17β-Hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer

Cancer Research

Volumn 64, Issue 20, 2004, Pages 7604-7609

  Oduwole, Olayiwola O ^a   Li, Yan ^a   Isomaa, Veli V ^a   Mäntyniemi, Anne ^a   Pulkka, Anitta E ^a   Soini, Ylermi ^a   Vihko, Pirkko T ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROTEIN SUBUNIT; SEX HORMONE; TESTOSTERONE 17BETA DEHYDROGENASE; TUMOR MARKER; 3 (OR 17) BETA HYDROXYSTEROID DEHYDROGENASE; 3 (OR 17)-BETA-HYDROXYSTEROID DEHYDROGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYDROXYSTEROID DEHYDROGENASE; ISOENZYME; KI 67 ANTIGEN; MESSENGER RNA; PARAFFIN;

ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME SUBUNIT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RNA ANALYSIS; SIGNAL DETECTION; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; STEROID METABOLISM; TUMOR VOLUME; BIOSYNTHESIS; BREAST TUMOR; ENZYMOLOGY; GENETICS; IN SITU HYBRIDIZATION; METABOLISM; MIDDLE AGED; PATHOLOGY;

17-HYDROXYSTEROID DEHYDROGENASES; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; ISOENZYMES; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM STAGING; PARAFFIN EMBEDDING; PROGNOSIS; RECEPTOR, ERBB-2; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 5644246147     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0446     Document Type: Article

References (42)

1. Vihko R, Apter D. Endogenous steroids in the pathophysiology of breast cancer. Crit Rev Oncol Hematol 1989;9:1-15.
2. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer. Cancer Res 1988;48:246-53.
3. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst (Bethesda) 1995;87:190-7.
4. Berrino F, Muti P, Micheli A, et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst (Bethesda) 1996;88:291-6.
5. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (Bethesda) 1998;90:1292-9.
6. Vermeulen A, Deslypere JP, Paridaens R, Leclercq G, Roy F, Heuson C. Aromatase, 17β-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 1986;22:515-25.
7. Geisler J, Berntsen H, Lonning PE. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. J Steroid Biochem Mol Biol 2000;72:259-64.
8. Peltoketo H, Vihko P, Vihko R. Regulation of estrogen action. Role of 17β-hydroxysteroid dehydrogenases. Vitam Horm 1999;55:35-98.
9. Puranen T, Poutanen M, Ghosh D, Vihko P, Vihko R. Characterization of structural and functional properties of human 17β-hydroxysteroid dehydrogenate type 1 using recombinant enzymes and site-directed mutagenesis. Mol Endocrinol 1997;11:77-86.
10. Wu L, Einstein M, Geissler WM, Chan HK, Elusion KO, Andersson S. Expression cloning and characterization of human 17β-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20α-hydroxysteroid dehydrogenase activity. J Biol Chem 1993;268:12964-9.
11. Puranen TJ, Kurkela RM, Lakkakorpi JT, et al. Characterization of molecular and catalytic properties of intact and truncated human 17β-hydroxysteroid dehydrogenase type 2 enzymes: intracellular localization of the wild-type enzyme in the endoplasmic reticulum. Endocrinology 1999;140:3334-41.
12. Miettinen M, Mustonen M, Poutanen M, et al. 17β-Hydroxysteroid dehydrogenase in normal human mammary epithelial cells and breast tissue. Breast Cancer Res Treat 1999;57:175-82.
13. Speirs V, Green AR, Atkin SL. Activity and gene expression of 17β-hydroxysteroid dehydrogenase type I in primary cultures of epithelial and stromal cells derived from normal and tumourous human breast tissue: the role of IL-8. J Steroid Biochem Mol Biol 1998;67:267-74.
14. Miettinen MM, Mustonen MV, Poutanen MH, Isomaa VV, Vihko RK. Human 17β-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression. Biochem J 1996;314:839-45.
15. Penning TM, Burczynski ME, Jez JM, et al. Structure-function aspects and inhibitor design of type 5 17β-hydroxysteroid dehydrogenate (AKRIC3). Mol Cell Endocrinol 2001;171:137-49.
16. Suzuki-Yamamoto T, Nishizawa M, Fukui M, et al. cDNA cloning, expression and characterization of human prostaglandin synthase. FEBS Lett 1999;462:335-40.
17. Desmond JC, Mountford JC, Drayson MT, et al. The aldo-keto reductase AKRIC3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. Cancer Res 2003;63:505-12.
18. Elston CW, Ellis IO. The breast, 3rd ed. Edinburgh: Churchill Livingstone, 1998.
19. WHO Technical Report Series No. 866. Research on the menopause in the 1990s. WHO: Geneva, Switzerland; 1996.
20. Mustonen MV, Poutanen MH, Kellokumpu S, et al. Mouse 17β- hydroxysteroid dehydrogenase type 2 mRNA is predominantly expressed in hepatocytes and in surface epithelial cells of the gastrointestinal and urinary tracts. J Mol Endocrinol 1998;20:67-74.
21. Peltoketo H, Isomaa V, Mäentausta O, Vihko R. Complete amino acid sequence of human placental 17β-hydroxysteroid dehydrogenase deduced from cDNA. FEBS Lett 1988;239:73-7.
22. Mäentausta O, Peltoketo H, Isomaa V, Jouppila P, Vihko R. Immunological measurement of human 17β-hydroxysteroid dehydrogenase. J Steroid Biochem 1990;36: 673-80.
23. Nandi S, Guzman RC, Yang J. Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci USA 1995;92:3650-7.
24. Cullen KJ, Lippman ME. Estrogen regulation of protein synthesis and cell growth in human breast cancer. Vitam Horm 1989;45:127-58.
25. Poutanen M, Isomaa V, Lehto VP, Vihko R. Immunological analysis of 17β-hydroxysteroid dehydrogenase in benign and malignant human breast tissue. Int J Cancer 1992;50:386-90.
26. Sasano H, Frost AR, Saitoh R, et al. Aromatase and 17β- hydroxysteroid dehydrogenase type 1 in human breast carcinoma. J Clin Endocrinol Metab 1996;81:4042-6.
27. Suzuki T, Moriya T, Ariga N, Kaneko C, Kanazawa M, Sasano H. 17β-Hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: correlation to clinicopathological parameters. Br J Cancer 2000;82:518-23.
28. Ariga N, Moriya T, Suzuki T, et al. 17β-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast. Anticancer Res 2000;20:1101-8.
29. Gunnarsson C, Olson BM, Stål O, Members of the Southeast Sweden Breast Cancer Group. Abnormal expression of 17β-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Res. 2001;61:4848-51.
30. Dufort I, Rheault P, Huang XF, Soucy P, Luu-The V. Characteristics of a highly labile human type5 17β-hydroxysteroid dehydrogenase. Endocrinology 1999;140:568-74.
31. Luu-The V, Dufort I, Pelletier G, Labrie F. Type 5 17β- hydroxysteroid dehydrogenase: its role in the formation of androgens in women. Mol Cell Endocrinol 2001;171: 77-82.
32. Miyoshi Y, Ando A, Shiba E, Taguchi T, Tamaki Y, Noguchi S. Involvement of up-regulation of 17β-hydroxysteroid dehydrogenase type 1 in maintenance of intratumorial high estradiol levels in postmenopausal breast cancers. Int J Cancer 2001; 94:685-9.
33. Klijn JGM, Berns EMJJ, Foekens JA. Prognostic and predictive factors and targets for therapy in breast cancer. In: Pasqualini JR, editor. Research cancer. New York: Marcel Fekker, Inc.; 2002. p. 93-124.
34. Gunnarsson C, Ahnstrom M, Kirschner K, et al. Amplification of HSD17B1 and ERBB2 in primary breast cancer. Oncogene 2003;22:34-40.
35. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 1992; 339:1-15, 71-85.
36. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997;57:4987-91.
37. Leygue E, Dotzlaw H, Watson PH, Murphy LC. Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast cancer. Cancer Res 1999;59:1175-9.
38. Harvey JM, Clark GM, Ostorne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
39. Järvinen TA, Pelto-Huikko M, Holli K, Isola J. Estrogen receptor β is co-expressed with ERα and PR and associated with nodal status, grade and proliferation in breast cancer. Am J Pathol 2000;156:29-35.
40. Fuqua SAW, Schiff R, Pana I, et al. Estrogen receptor β protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 2003;63:2434-9.
41. Hall JM, McDonnel DP. The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999;140:5566-78.
42. Jukkola A, Bloigu R, Soini Y, Savolainen ER, Holli K, Blanco G. c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer 2001;37:347-54.